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Summary In this study we demonstrate that the hemopoietic growth factor, G-CSF successfully mobilised
progenitor cell populations into the peripheral blood in a population of patients despite intensive pretreatment
with chemotherapy. Administration of G-CSF increased the numbers of peripheral blood progenitor cells
(PBPC) by a median of 76-fold above basal levels. Maximal levels of PBPC were observed on days 5 and 6
after G-CSF treatment. In two patients a second cycle of G-CSF mobilised PBPC to levels comparable with
those seen after the first cycle of G-CSF treatment. An earlier hemopoietic cell population (pre-CFC's) was
also mobilised with levels increased up to 50-fold above basal levels.
Using a standard mononuclear cell leukapheresis technique the PBPC were collected extremely efficiently
(essentially 100%) and could be further successfully enriched by separation using a Ficoll gradient. For
patients who underwent the optimal collection protocol (i.e. leukapheresis on days 5, 6 and 7) a total of
32 ± 6 x 104 GM-CFC kg- ' were collected.
The ability to mobilise PBPC using G-CSF alone and to successfully and efficiently harvest these cells has
important implications for the future of transplantation and high dose chemotherapy procedures.
Granulocyte colony stimulating factor (G-CSF), one of the
family of hemopoietic regulators (Nicola, 1990) is able to
stimulate proliferation of neutrophil progenitor cells in vitro
(Metcalf & Nicola, 1983). The characterisation (Nicola et al.,
1979) and molecular cloning of this molecule (Nagata et al.,
1986) has allowed its evaluation in a variety of clinical
settings including for example, administration of G-CSF to
patients following high dose chemotherapy and bone marrow
transplantation (Sheridan et al., 1989).
In addition, studies of both G-CSF (Duhrsen et al., 1988;
Gabrilove et al., 1988) and GM-CSF (Socinski et al., 1988;
Villeval et al., 1990) have shown an unexpected ability of
these growth factors to mobilise progenitor cells into the
peripheral blood, leading to a 100-fold increase in total
numbers being observed after G-CSF administration. In con-
trast, Multi-CSF (or IL-3) appears to induce only a 2-fold
increase in PBPC (Ottoman et al., 1990).
Autologous bone marrow transplantation is being increas-
ingly used to allow administration of high dose chemo-
therapy for the treatment of various malignancies. Following
high dose chemotherapy, there is a period of pancytopenia
during which patients are at risk from infection and haemor-
rhage until the infused marrow cells repopulate the peripheral
blood with mature progeny. In an attempt to circumvent
some of these problems, peripheral blood progenitor cells
(PBPC) have been used to accelerate hemopoietic regenera-
tion. Several groups have reported that PBPC can be mobil-
ised by chemotherapy, collected cryopreserved and used
subsequently to rescue patients following high dose chemo-
therapy (To et al., 1984; Richman et al., 1976). The use of
PBPC collected under normal basal conditions has limited
application because of the very low levels of progenitor cells
found under conditions of steady-state hemopoiesis (Stiff et
al., 1986; Barr & McBride, 1982).
The present study focuses on analysing the characteristics
of PBPC collected by leukapheresis following administration
of G-CSF alone.
Materials and methods
Criteriafor eligibility and description ofpatients
Two groups ofpatients were eligible to receive G-CSF in this
study. One group involved patients with non-myeloid malig-
nancies who were in remission after initial chemotherapy but
had poor prognostic features (acute lymphoblastic leukaemia
and non-Hodgkin's lymphoma). The other group of patients
were those with an inadequate response to, or in relapse after
prior chemotherapy (acute lymphoblastic leukaemia, non-
Hodgkin's lymphoma, Hodgkin's disease and germ cell
tumour) (Table I). This study was undertaken at the Royal
Table I Patient characteristics
Prior chemotherapy Time since
No No cycles last
Remission different of treatment
Age Sex Diagnosis status regimens treatment (weeks)
23 F NHL 2nd PR 4 11 8
50 F NHL 2nd CR 2 7 2
23 F NHL Ist PR 2 2 12
40 F NHL 3rd PR 4 7 3
35 M NHL 2nd CR 2 8 9
26 F NHL Ist PR 1 1 20
52 M NHL 2nd PR 3 >8 5
42 M NHL Ist PR 2 15 18
43*2 M NHL 2nd PR 3 4 8
49 F NHL Ist CR 2 2 7
39 F NHL 4th CR 5 >6 7
36*1 F ALL Ist CR 3 12 9
26 F ALL Ist CR 5 7 9
27 M ALL Ist CR 3 20 7
20 M ALL Ist CR 6 6 10
19 M ALL Ist CR 2 4 5
33 M ALL 2nd CR 6 9 5
15 M ALL Ist CR 3 3 13
28 M ALL Ist CR 3 4 6
34 F HD 3rd PR 2 15 56
21 M HD 3rd PR 5 21 8
Abbreviations: NHL - non-Hodgkin's lymphoma; ALL - acute
lymphoblastic leukaemia; HD - Hodgkins; CR - complete remission;
PR-partialremission. ReferstoPatient 1 (*i) andPatient2(*2)inTable
V.
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Melbourne Hospital, Royal Adelaide Hospital and Alfred
Hospitals under the ethical guidelines of the National Health
and Medical Research Council of Australia and the Food
and Drug Administration of the USA (Sheridan et al., 1992).
All patients gave informed consent. Patient accrual com-
menced in December 1989 and results from a subset of 21
patients studied in the one laboratory are presented in this
paper.
Properties ofG-CSF
Recombinant human Granulocyte Colony-Stimulating Factor
(G-CSF) (Amgen Corp., Thousand Oaks, CA) has a molec-
ular weight of 18,800 daltons. It differs from the native
protein in that the N-terminal amino acid is a methionine
and the protein is not 0-glycosylated. The G-CSF protein
was produced in Escherichia coli and purified using a series
of chromatographic steps. The final product was formulated
in an aqueous buffer as a sterile solution and shown to be
biologically active and free of pyrogens.
Collection protocolfor PBPC
Prior to G-CSF treatment leukapheresis was performed to
determine baseline levels of PBPC. Patients then received
12figkg-' day-' of G-CSF for either 6 or 7 days via con-
tinuous subcutaneous infusion through a 23 gauge needle
connected to a Comed infusion pump. Leukapheresis was
performed on either consecutive days (days 5, 6, and 7;
n = 13) or alternate days (days 4, 6 and 8; n = 8) on different
patients, using a Fenwal CS-3000 cell separator (Baxter,
Deerfield, Illinois) with the red cell interface set at 020 units.
Each leukapherisis involved processing a minimum of 7 litres
of blood. At the end of processing, an aliquot of collected
cells was removed for subsequent progenitor cell assay.
Processing ofblood samples
Peripheral blood and leukapheresis samples were collected on
the days indicated above. Samples were washed and sub-
jected to gradient centrifugation for 20min, at 400g using
Ficoll-Paque (density 1.077 gml-1, Pharmacia, Inc., Uppsala,
Sweden). The light density interface cells were collected,
washed and resuspended in RPMI 1640 with 10% foetal calf
serum (FCS). Staining of the interface cells with May-Grun-
wald - Giemsa indicated that approximately 60% of the cells
present in this fraction were lymphocytes, 30-40% were
monocytes with low numbers of myeloblasts, promyelocytes,
metamyeloblasts and normoblasts. There was no significant
difference in cell type distribution at the light density inter-
face before and after G-CSF treatment. After Ficoll separa-
tion, cells in the pellet were >95% mature neutrophils with
the remainder of cells being band forms.
Progenitor cell assay
Progenitor cells were grown in agar culture prepared by
adding 1 vol of double strength Iscove's modified Dulbecco's
medium (IMDM) and 1 vol of FCS to 2 vol of 0.6% agar in
a final volume of 1 ml (Metclalf, 1984). Cultures were stim-
ulated by 500 units of purified recombinant human G-CSF
(Amgen, CA, USA specific activity, -1IO U mg-') dissolved
in 0.1 ml of saline and 1,500 units of purified recombinant
human GM-CSF (Schering-Plough, specific activity, 5 x 108
Umg-'). Additional cultures were stimulated with recom-
binant human erythropoietin (EPO: a gift from Dr A. Bur-
gess - Ludwig Institute for Cancer Research, Melbourne and
titrated to be a maximal stimulus at a dilution of 1:100 or
purchased from Cilag AG, International, Switzerland and
used a 5 Uml-') plus 100,sl of pre-titrated human placental
conditioned medium (HPCM). Cells from peripheral blood
leukapheresis were cultured both at 2 x 105 and 4 x 105 cells/
dish. In control experiments adherence depletion techniques
did not result in an increase in the number of colonies
generated. Cultures were incubated in a humidified atmos-
phere of 5% CO2 in air at 37°C for 14 days. Replicate
cultures were scored after 14 days using a dissection micro-
scope at 35 x magnification. Clones of more than 40 cells
were scored as colonies.
Pre-CFC assay
To detect the presence of an earlier hemopoietic cell popula-
tion (pre-CFC's), light density mononuclear cells were col-
lected from the leukapheresis product and a pre-CFC assay
performed as previously described (Moore et al., 1980).
Briefly, adherence depletion prior to liquid culture was per-
formed by incubating not more than 0.4 x 106 cells cm-2 in a
culture flask (Nunclon, Denmark) for 1 h, at 37°C in a
humidified incubator with 10% CO2 in air. Non-adherent
cells were removed and 1 x 106 cells ml-' were cultured for 7
days in RPMI plus 10% FCS which also contained an
optimal HPCM concentration. After the liquid culture phase,
cells were collected, washed and resuspended in 500 LI RPMI
plus 10% FCS. An aliquot was then cultured in agar
together with GM-CSF (1,500 U ml1'), HPCM (100glIml-')
and EPO (5 U ml-', Cilag). Colonies were scored on day 14.
In some experiments no initial adherence depletion was per-
formed, and the mononuclear cells were cultured for 7 days
as described.
For all samples a colony assay was performed prior to the
liquid culture phase to quantitate number of input colony
forming cells (CFC's).
Staining ofcultures
Whole plate staining was performed by fixing agar cultures
with 2.5% glutaraldehyde and floating them onto glass slides.
Plates were air dried and stained with Luxol fast blue and
haematoxylin (Metcalf, 1984).
Results
Efficient collection ofG-CSFmobilised PBPC
Initial experiments were performed to examine the efficiency
ofcollection of G-CSF mobilised PBPC using a leukapheresis
technique. This was determined by enumerating PBPC detec-
table both in peripheral blood and in blood returning to the
patient at the end of the leukapheresis collection (return line
sample). Table II shows that the leukapheresis collection
procedure was extremely efficient both prior to G-CSF and
after G-CSF treatment. For patients with a normal white cell
count and normal levels of circulating PBPC, leukapheresis
collection was very efficient with no PBPC detected in the
return line sample. Similarly, for patients wth markedly
elevated white cell counts and >3000 Granulocyte-Macro-
phage (GM)-CFC per ml the leukapheresis procedure
extracted essentially all PBPC as none were detected in blood
samples from the return line.
Because density separation using a Ficoll gradient is fre-
quently used clinically to concentrate the leukapheresis prod-
uct, we examined the distribution of G-CSF mobilised PBPC
after separation on a Ficoll gradient. The data presented in
Table III shows that prior to G-CSF, virtually 100% of
PBPC in the leukapheresis product were of light density
(<1.077g ml-') and were collected at the interface layer.
Similarly, after G-CSF treatment even though numbers of
PBPC were markedly increased, 98% were of light density
and recovered at the interface layer. Thus, Ficoll gradient
separation served as a rapid and efficient method enriching
for the vast majority of G-CSF mobilised PBPC.
Elevatedprogenitor cell levels after G-CSF treatment
The white cell count (WCC) and progenitor cell levels were
determined in peripheral blood and leukapheresis samples of
patients before treatment with G-CSF and then on either
days 4, 6 and 8 or days 5, 6, and 7 after administration ofG-CSF MOBILISED PROGENITOR CELLS 895
Table II Efficientcollection ofcirculating peripheral bloodprogenitor
cells
Experiment Peripheral blood Return line sample
no. WCC x 16 1-I GM-CFCml' GM-CFC ml-a
1 3.9 14 0
2 36 670 0
3 49 310 0
4 59 3333 0
5 70 3150 0
The WCC and GM-CFC ml-I peripheral blood were determined
before and after treatment with G-CSF. The results are mean values
from replicate cultures. Experiment I represents the result obtained
beforeG-CSF treatment. Experiments 2-5aretheresultsobtainedafter
G-CSF treatment. aCFC were undetected in all cases (minimum of
4 x 105 mononuclear cells analysed).
Table III Distribution of GM-CFC after Ficoll separation of
leukapheresis product
Total GM-CFCml-' % at interface
Interface Pellet
Control 442± 335 <0.25 100%
After G-CSF 37427±6760 522±227 98%
The results shown are the mean±s.e.m. for three patients (in control
group) or six patients (after G-CSF treatment).
G-CSF. Subcutaneous infusion of 121g kg-' day-' of G-
CSF increased the peripheral blood WCC from a baseline of
5.02 ± 2.37 x lO9cells l' to 34 ± 17 x IO9 cells -' by day 4
(mean increase of 6-fold) (Figure 1). This level was main-
tained with continued treatment of G-CSF. As expected,
progenitor cell assays performed on peripheral blood samples
showed low levels of PBPC (39 ± 15 GM-CFC ml-' blood)
before G-CSF treatment. Although there was considerable
heterogeneity in response, maximum levels of PBPC were
observed after 5 days of G-CSF administration. As pre-
viously reported (Diihrsen et al., 1988) increases were
observed in all cell lineages (see below). GM-CFC were
increased up to 3000-fold (median increase in 76-fold)
(Figure 1). As shown in Figure 1, increases of up to 3000-
fold (median increase of 38-fold) were also observed for day
14 erythroid progenitors. Thus, although there was a median
increase in the peripheral WCC of approximately 8-fold dur-
ing G-CSF treatment, there was a disproportionate increase
of approximately 40-80-fold in levels of PBPC.
Total mononuclear cell counts and progenitor cell levels
were also analysed in the leukapheresis product (Figure 2).
Consistent with the observed increase in blood WCC follow-
ing treatment with G-CSF, a 5-fold median increase was seen
in total mononuclear cells collected by leukapheresis. In con-
trast there was an increase in GM-CFC of up to 5300-fold
above baseline (median increase of 62-fold) and in erythroid
progenitors of up to 8000-fold (median increase of 47-fold)
(Figure 2). Similar increases were also observed in eosinophil
progenitor and multipotential progenitor cells in the leuka-
pheresis samples (Table IV). Thus, the changes observed in
the leukapheresis product were in keeping with those seen in
the peripheral blood, with median increases of 50-60-fold in
progenitor cell levels compared with a median increase of
only 5-fold in total cell counts.
Comparison ofcollection schedules
Comparison of samples from patients undergoing leukapher-
esis on days 5, 6 and 7 with days 4, 6 and 8 showed no
significant differences in the total number of mononuclear
cells harvested. However there were significant differences in
the number of PBPC collected on different days. Figure 3
shows the number of GM-CFC collected from patients on
days 4-8. Maximum numbers ofGM-CFC were collected on
day 5 and fewer progenitor cells were harvested after that
time. Between 2-3-fold fewer GM-CFC were collected on
days 4 (P<0.02), 7 (P<0.03) and 8 (P<0.04) (Student t-
test). Similar results were obtained for erythroid, eosinophil
and multipotential progenitor cells (data not shown). The
number of progenitor cells collected by the two collection
schedules (days 4, 6, 8 vs days 5, 6, 7) was also compared
(Figure 3). It was of interest to note that there was no
difference in the number of GM-CFC harvested at day 6
using the two collection protocols. Therefore the decline in
number ofprogenitor cells seen with the day 5, 6, 7 collection
schedule may reflect a true biological response to G-CSF
rather than simply being a consequence of collections on
consecutive days. Conversely the day 4, 6, 8 schedule was not
associated with heightened levels of progenitor cells that
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Figure 1 Total white cell count (per litre ofperipheral blood) and PBPC levels per ml ofperipheral blood determined on days 0, 4,
6, and 8 (n = 8); (0) or days 0, 5, 6 and 7 (n = 13); (-) of G-CSF treatment are presented. These results were obtained from a
total of 21 different patients where each point represents mean values from replicate cultures stimulated with either GM-CSF and
G-CSF to quantitate non-erythroid colonies (GM-CFC) or with EPO and HPCM to quantitate erythroid colonies.
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Figure 2 Total mononuclear cell count (per litre of leukapheresis sample) and frequency of day 14 CFCs per ml of the
leukapheresis product collected on days 0, 4, 6 and 8 (n = 8); (0) or days 0, 5, 6 and 7 (n = 13); (@) of G-CSF treatment are
presented. The results were obtained from a total of 21 different patients where each point represents mean values from replicate
cultures stimulated with either GM-CSF and G-CSF to quantitate non-erythroid colonies (GM-CFC) per ml leukapheresis or with
EPO and HPCM to quantitate erythroid colonies.
Table IV Morphology of colonies from leukapheresis samples
Percentage ofnon-erythroid Number colonies, per ml
colonies (x 104)
M GM Eo Mixed Non-erythroid Erythroid
Baseline 22 54 21 2 0.36 0.47
12 48 37 3 0.055 0.22
19 69 12 0 0.005 0.007
Day5 17 51 23 9 3.5 1.1
9 51 27 13 2.8 4.4
12 47 29 12 6.4 5.2
Colonies were examined from cultures stained with Luxol fast blue
and haematoxylin and were classified as pure erythroid colonies or
non-erythroid colonies (macrophage (M), neutrophil-macrophage
(GM), eosinophil (Eo), multipotential (mixed)). A minimum of 90
consecutive colonies were examined except for patient three baseline
values (16 colonies). Results are shown prior to receiving G-CSF
(Baseline) and after 5 days of G-CSF treatment. The total number of
pure-erythroid and non-erythroid colonies per ml of leukapheresis
sample is shown.
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Figure 3 Comparison of the total number of non-erythroid col-
onies (GM-CFC) ml-' of leukapheresis collected on consecutive
days (5, 6 and 7, open bars) or alternate days (4, 6 and 8, closed
bars). The data is mean±s.e.m. of results obtained from the 21
patients in Figure 2.
might have been predicted given the 'rest' day between collec-
tions.
The total number of GM-CFC harvested using these two
schedules was also compared. Harvesting on days 4, 6, 8
produced a total of 1.2± 0.47 x 107 GM-CFC compared
with 2.02 ± 0.37 x 107 GM-CFC on days 5, 6, 7. Although
because of patient to patient heterogeneity the total number
of GM-CFC collected on days 4, 6, 8 was not statistically
different from the total number collected on days 5, 6, 7
(P<0.2), seven of the 13 patients on the consecutive day
collection schedule achieved levels of GM-CFC kg-' greater
than the number required for reconstitution (i.e. 30 x 104
GM-CFC kg-') (To et al., 1986). In contrast only one of the
eight patients on the alternate day collection protocol had
greater than 30 x 104 GM-CFC kg-'. This suggests that the
preferred schedule for harvesting maximal number of G-CSF
mobilised PBPC was days 5, 6, 7.
Mobilisation ofPBPC after two cycles G-CSF
In an attempt to maximise PBPC collected by leukapheresis,
two patients received two cycles of G-CSF with 10 weeks
(Patient 1) or 5 weeks (Patient 2) between cycles. The WCC
and number of GM-CFC collected are presented in Table V.
For patient 1 there was a poor response to G-CSF in the first
cycle with only a 4-fold increase observed in the WCC. A
similar low level response was observed after administration
of the second cycle of G-CSF. Low levels of GM-CFC were
observed in the leukapheresis product after both the first
(7.2 x 104 GM-CFC kg-') and second (6.4 x 104 GM-CFC
kg-') cycle of G-CSF. For patient 2, G-CSF increased the
WCC by approximately 9-fold and a similar effect was
observed with the second cycle of G-CSF therapy. As with
patient 1, there was no difference in GM-CFC levels obtained
in the leukapheresis product after 1 or 2 cycles of G-CSF.
Thus, a prior cycle of G-CSF did not appear to influence
subsequent mobilisation of PBPC eithuer positively or nega-
tively and a poor response to the first cycle predicted a poor
response to the second cycle of G-CSF.
G-CSFmobilises Pre-CFC
To determine whether an early population of progenitor cells
('pre-CFC') was mobilised by G-CSF and could be detected
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Table V Progenitor cell levels and white cell count following two cycles G-CSF
Total WCC GM-CFCml-' GM-CFCper GM-CFCkg-'
(x 1091-') (x 104) Leukapheresis (x 10J) (x JO4)
Day Cycle I Cycle 2 Cycle I Cycle 2 Cycle 1 Cycle 2 Cycle 1 Cycle 2
Patient 1
0 4.4 2.96 0.011 <0.002 2.18 <0.37 0.038 <0.006
5 16.35 19.8 0.68 0.42 135.4 83.9 2.33 1.45
6 16.32 15.5 1.16 0.372 233 74.4 4.01 1.28
7 7.0 13.9 0.24 1.06 47.9 212.2 0.83 3.66
Total 7.2 6.4
Patient 2
0 2.94 3.16 0.063 0.008 12.6 1.5 0.189 0.023
4 19.2 21.4 3.3 3.7 660 740 9.94 11.14
6 19.08 29.4 3.7 3.4 740 680 11.1 10.24
8 23.7 31.3 3.4 4.9 680 980 10.2 14.76
Total 31.3 36.1
Progenitor cell data represents mean value obtained from replicate cultures. See Table I for patient
details.
in the leukapheresis product, mononuclear cells were cultured
in liquid for 7 days then CFC's quantified using a clonal
assay as previously described (Moore et al., 1980). The
number of CFC generated during the liquid culture phase
was compared to the number of input CFC. In the experi-
ments shown in Figure 4, the number of CFC generated was
up to 60-fold greater than input CFC. Because greater
numbers of CFC were frequently generated after liquid cul-
ture compared to the number of input colonies it seemed
unlikely that colonies generated after liquid culture simply
reflected survival of input progenitor cells. However, as was
the case with the progenitor cell levels, the pre-CFC data also
showed considerable variation from patient to patient. This is
partly illustrated in Figure 4 where one can see the variability
in the ratio of input to output colony numbers. Accordingly
as a result of treatment with G-CSF, there was an increase in
levels ofpre-CFC ranging between 15-50-fold above baseline
values.
Figure 5 compares the increase in pre-CFC and GM-CFC
for samples taken from six patients, on days 5, 6, and 7 after
G-CSF treatment. A 15-fold mean increase in pre-CFC
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Figure 4 Comparison of the input number of CFC with number
of colonies generated after liquid culture. Adherence depleted
mononuclear cells obtained from the leukapheresis product after
G-CSF treatment (on either days 5, 6 and 7) were either directly
cultUred in agar (to determine input CFC) or cultured for 7 days
and then assayed in clonal culture ('pre-CFC'). The results pre-
sented are from six different experiments where each point repre-
sents mean values from replicate cultures stimulated with a com-
bination of GM-CSF, HPCM and EPO.
above baseline was observed on day 5 compared with a
30-fold mean increase in GM-CFC. A similar increase in
pre-CFC's was evident on day 6 with a mean increase of
6-fold on day 7. It was interesting to note the apparent
dissociation between the fold increase in GM-CFC compared
with pre-CFC on day 5 possibly reflecting differences in the
kinetics of release in response to G-CSF. These results gave
further support for the view that the pre-CFC assay and
GM-CFC assay were assessing different populations of cells.
This data therefore suggests that G-CSF was able to mobilise
earlier populations of cells (pre-CFC) that were also success-
fully collected by leukapheresis.
Discussion
This study demonstrated that G-CSF can be used to success-
fully mobilise progenitor and pre-CFC populations into the
blood even in a population of patients heavily pretreated
with chemotherapy (Table I). These PBPC were then harvest-
ed efficiently using a Fenwal CS-3000 cell separator. The fact
that PBPC were efficiently collected using the same machine
parameters both before and after G-CSF treatment suggested
that the G-CSF mobilised cells shared similar physical pro-
perties to PBPC in the resting state. In both situations no
CFC were detected in blood returning to the patient. The
resting and G-CSF mobilised PBPC also showed similar
density characteristics as assessed by behaviour on a Ficoll
gradient. As indicatd in Table III virtually 100% of GM-
CFCml1' in the leukapheresis produce were present at the
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Figure 5 Comparison of fold increase above baseline observed
for GM-CFC and pre-CFC. Results are mean±s.e.m. from six
different patients for each CFC population. The comparison
between GM-CFC and pre-CFC was performed between leuka-
pheresis samples from the same patient.
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interface layer for both the resting PBPC and G-CSF mobil-
ised PBPC. This is of particular clinical importance as
leukapheresis samples are frequently further processed using
a Ficoll gradient to enrich for mononuclear cells prior to
transplantation. Our data demonstrate that these techniques
can be efficiently used to obtain maximum numbers of G-
CSF mobilised progenitor cells.
Following administration of G-CSF, as expected, the peri-
pheral blood white cell count increased by a median of 8-fold
above baseline levels. In contrast, the levels of GM-CFC
increased by a median of 40 or 60-fold above baseline levels
in the peripheral blood or leukapheresis product respectively.
This vast difference indicates two events occuring as a result
of G-CSF administration. One involves increased numbers of
neutrophils via a likely demargination and a later prolif-
erative effect on granulocyte precursors and the other
involves the action of G-CSF on a population of progenitor
cells leading to the mobilisation of large numbers of CFC
into the peripheral blood. As a result, there were increased
numbers of GM-CFC, day 14 erythroid progenitors (Figure
1), eosinophil-CFC and multi-CFC (Table IV). This action of
G-CSF was not predicted from the known action of G-CSF
in vitro and is supported by other studies that also demon-
strated an increase in megakaryocyte and eosinophil CFC's
at G-CSF concentrations as low as 3 tLgkg-' day-' (Diihrsen
et al., 1988). While similar results have been reported for
GM-CSF, the number of GM-CFC mobilised PBPC appears
at least 10-fold lower than in this current study, but a direct
comparison has not been performed. Studies with Multi-CSF
(IL-3) showing only a 2-fold increase in PBPC suggests a
'hierarchy' of response in terms of ability to mobilise PBPC.
Other hemopoietic regulators may also have important clini-
cal applications in the future. Various animal models (Ulich
et al., 1991; Andrews et al., 1991) have been used to study
the effect of the recently described kit-ligand or stem cell
factor (SCF) in vivo (Zsebo et al., 1990). The action of SCF
in humans either alone or in combination, however, remains
to be determined.
We were also interested in determining whether G-CSF
was able to mnobilise pre-CFC into the peripheral blood.
Murine studies (Nicola & Johnson, 1982) have shown that a
population of pre-CFC could be assayed by culturing frac-
tionated fetal liver cells in liquid culture over 7 days in a
crude mixture of factors (pokeweed mitogen-stimulated
spleen cell-conditioned medium). Similar studies used human
bone marrow cells grown in liquid culture in HPCM to assay
a population of pre-CFC (Moore et al., 1980) which could
then be maintained in long-term culture in the presence of an
adherent layer. In this study we also used this technique to
assay pre-CFC. In this assay, the number of CFC generated
was consistently greater than input CFC, implying that CFC
were being generated during the liquid culture phase. In
studies using murine fetal liver cells (Nicola & Johnson,
1982), the CFC population died within 5 days while the
pre-CFC population reached a maximum at this time. Simi-
lar results have been shown for human CFC where the
number of GM-CFC fell after 4 days in suspension culture
(Jacobsen et al., 1979). It seems likely then that in addition
to its effect on mobilising CFC of all lineages G-CSF was
also able to mobilise a population of pre-CFC. The increase
in this earlier cell population was only up to 50-fold (com-
pared with increases of up to 3000-fold for GM-CFC) and
with kinetics suggesting that these cells might be mobilised
somewhat later than CFC.
Other studies have utilised cytotoxic drugs with or without
CSF's to mobilise PBPC (Gianni et al., 1989; To et al., 1990). Although useful in some situations, such protocols are assoc-
iated with the side-effects of chemotherapy, are less applic-
able in patients who have had recent intensive chemotherapy
and require administration of drugs that may be relatively
inactive in particular malignancies. The protocol described in
this study may be more widely applicable because it is not
associated with these problems - the only side effects being
mild bone pain during G-CSF administration and thrombo-
cytopenia during leukapheresis (requiring platelet transfusion
in two patients of 21) (Sheridan et al., 1992). In addition the
yield of PBPC using chemotherapy techniques (without addi-
tion of CSF's) is 10-100-fold less than with G-CSF alone
(Gabrilove et al., 1988; To et al., 1984). However, based on
chemotherapy mobilised PBPC a minimum number of
30 x 104 GM-CFC kg-' is estimated to be required for subse-
quent engraftment using PBPC transfusion alone (To et al.,
1986). When reinfused, chemotherapy mobilised PBPC
hasten neutrophil and platelet recovery following high dose
chemotherapy. Similar accelerated platelet recovery was
observed when the G-CSF mobilised PBPC from this study
were reinfused following high dose chemotherapy (Sheridan
et al., 1992).
There was considerable variability in responses to G-CSF.
This most probably reflects the heterogeneity in this heavily
pre-treated group of patients. In addition there was vari-
ability for each patient between the period since having last
received myelotoxic chemotherapy treatment and entry onto
the study (Table I). Thus these patients would be expected to
have different hemopoietic stem cell reserves leading to the
variable response to G-CSF although intrinsic individual
variation might also be expected in response to G-CSF. This
issue could be better addressed in patients who had not
received prior chemotherapy. Despite this variation, this
technique was successful in harvesting > 30 x 104 GM-CFC
kg-' in eight of 21 patients.
Two alterations in the collection protocol were analysed in
an attempt to optimise mobilisation and collection of PBPC.
One addressed the question of leukapheresis collection
schedule. It was possible that harvesting of progenitor cells
on consecutive days may have contributed to the decline in
PBPC levels between days 5 and 7. Therefore, progenitor
cells were subsequently harvested on days 4, 6 and 8. This
did not increase the number of PBPC obtained on alternate
days and actually resulted in half the total number of PBPC
being collected due to lower levels at day 4 and 8. A second
approach involved the administration of two cycles of G-
CSF. In two patients there was no difference in the ability of
G-CSF to mobilise progenitor cells after one or two cycles of
G-CSF.
The mechanism involved in G-CSF induced PBPC mobili-
sation is unknown. Several studies have failed to demonstrate
an increase in progenitor cells in bone marrow in response to
G-CSF (Diihrsen et al., 1988), GM-CSF (Socinski et al.,
1988; Haas et al., 1990) or Multi-CSF (IL-3) (Ottoman et al.,
1990). In addition the appearance of circulating progenitor
cells of all lineages suggests a non-specific mechanism that
can be triggered by general insults (such as chemotherapy) as
well as by the hemopoietic regulators. However, this mechan-
ism appears not to be totally non-specific as one of the most
common subpopulations of bone marrow progenitor cells
(day 7 GM-CFC) was not observed in the circulation after
G-CSF treatment and furthermore, administration of IL-4
did not mobilise progenitor cells into the peripheral blood
(De Luca et al., unpublished results).
In summary, the ability to mobilise and collect PBPC using
this non-toxic and efficient procedure has important implica-
tions for transplantation and high-dose chemotherapy proce-
dures.
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